Prof. Dr. Yeşim ERALP

Prof. Dr.
Yeşim ERALP

Cancer Center / Oncology

Make An Appointment
Hospitals 
  • Gayrettepe Florence Nightingale Hospital Cemil Aslan Güder Sok. No: 8 Gayrettepe - İstanbul Show in Map
  • Part-Time, Consultant Works

Dr. Yeşim ERALP has graduated from Istanbul University Istanbul Medical Faculty in 1991. She completed her post-doctoral training as a resident at the Cerrahpaşa Medical Faculty Department of Internal Medicine between 1992 and 1997; and as a fellow of Medical Oncology at Istanbul University Institute of Oncology between 1998 and 2001. In 2002 she was accepted as a post-doctoral fellow at the Department of Bio-immunotherapy, University of Texas MD Anderson Cancer Center, where she received further training to improve her skills in basic oncology and immunotherapy with viral based cancer vaccines. She also developed expertise in integrated clinical management of patients at the department of Breast Medical Oncology of the same Institution during her post-doctoral training. 
 
After returning to the Istanbul University Institute of Oncology, she was appointed as Associate Professor in 2004 and as the Co-chair and member of the Executive Board of Directors in 2006, where she devoted herself to curricular development, excellence in education and academic activities. She received her degree as Professor of Medicine and Medical Oncology in 2009 at the same Institution. 

Dr. Eralp has developed profound conceptual skills and expertise necessary to provide the highest quality of clinical care in oncology.  She is an active opponent of integrative approaches and multidisciplinary management in cancer care. She is a prominent national leader in her field and is an invited lecturer in numerous conferences, collaborating to share ideas and provide effective means to utilize the available academic information. She is involved in the clinical care of all patients with solid tumors, with special interest in the multidisciplinary management of breast, thoracic, gynecologic, gastrointestinal cancers and malignant melanoma. She has prioritized personalized cancer care directed to target the biologic specifications of the tumor, as well as the needs of the patient. Based on her previous training in immune-oncology, she has been able to adopt the latest evidence-based immunotherapeutic approaches in her daily practice and has treated many patients successfully with immunotherapy and targeted agents. 

    • Date of Birth 1968
    • Spoken Languages Tr, Eng
  • Videos
  • News
Today
  • 2009 Professor of Medical Oncology Istanbul University Institute of Oncology Istanbul University, Istanbul Medical Faculty, Dept of Internal Medicine
  • 2006 - 2010 Co-chair and member of the Executive Board of Directors Directing and strategic planning in educational and research activities Istanbul University Institute of Oncology
  • 2004 - 2009 Associate professor of Medical Oncology Teaching basic aspects of medical oncology to medical students and residents, Planning, conducting and actively taking part in clinical and basic research involving breast, lung and gynaecologic cancers, Integrated treatment planning and consultation for cancer patients in multidisciplinary clinic meetings, Clinical practice 5 days a week Istanbul University Institute of Oncology and Istanbul University Istanbul Medical Faculty, Dept. Of Medical Oncology University Hospital
  • 2002 Postdoctoral Fellow; Dept. of Bioimmunotherapy Visiting Medical Oncologist ; Dept of Breast Medical Oncology İmprove basic research skils and gain insight into innovative immunotherapeutic approaches for breast cancer; planning and conducting basic research involving a virus-based vaccine developed for Her-2/neu positive breast cancer Improve understanding of clinical management for breast cancer and conduct retrospective clinical research University of Texas, M.D. Anderson Cancer Center, Houston, Texas
  • 2001 - 2004 Specialist and consultant of Medical Oncology Actively taking part in scientific projects involving breast, lung and gynaecologic cancers, Clinical practice 5 days a week, Clinical consultant Istanbul University Institute of Oncology and Istanbul University Istanbul Medical Faculty, Dept. Of Medical Oncology University Hospital
  • 1998 - 2001 Istanbul University Institute of Oncology and Istanbul University Istanbul Medical Faculty, Dept. Of Medical Oncology Specialist in Medical Oncology Integrative treatment planning and treating patients with cancer Working in and directing in-patient and outpatient clinics involving cancer patients
  • 1992 - 1997 Working and directing in-patient and out-patient clinics treating patients with internal diseases Istanbul University Cerrahpasa Medical Faculty Specialist in Internal Medicine Integrative treatment planning and treating patients with internal diseases
  • 1985 - 1991 Istanbul University Istanbul Medical Faculty, School of Medicin Medical Doctor Insight into practicing general medicine
  • 1978 - 1985 Istanbul American Robert College High School Excellent spoken and written English Integrative education classes covering basic and higher level

  • American Society of Medical Oncology (1998-2002)
  • European Society of Medical Oncology (1998-2002)
  • Turkish Society of Medical Oncology (1998-present) 
  • Society of Pulmonary Malignant Diseases (2003-present)
  • Turkish Federation of Breast Diseases (2004-present)
  • Istanbul Society of Breast Cancer (2004-present)

Publications

The articles that are published in International Refereed Journals

1. Dobrucalı A, Tuncer M, Eralp Y, Göksel S, Altın M, Dinç İ, “One-day high dose combined therapy of H. Pylori infection,” Dig Dis Sci, 42(10), 2169-70 (letter) (1997).

2. Dobrucali A, Canbakan B, Canbakan M, Bagatur N, Uzunismail H, Eralp Y, Akün E,Göksel S, Yurdakul I, Oktay E, “Metaanalyse zur feststellung der keimeradizierenden potenz verschiedener therapieschemata bei H. Pylori infektion,” Wiener Medizinische Wochenschrift, 148(20), 464-8 (1998).

3. Taş F, Aydıner A, Topuz E, Çamlıca H, Saip P, Eralp Y, “Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer,” Acta Oncol, 38(8),1011-5 (1999).

4. Eralp Y, Bavbek S, Başaran M, Kaytan E, Yaman F, Eralp L, Özger H, Bilgiç B, Kalaycı G, Onat H, “Prognostic factors and survival in patients with metastatic soft tissue sarcoma,” J Balkan Union Oncol, 5,281-6 (2000).

5. Topuz E, Aydıner A, Saip P, Eralp Y, Taş F, Salihoğlu Y, Berkman S, Bengisu E, “Correlations of serum CA-125 levels and computerized CT imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer,” Eur J Gyn Oncol, 2(6),599-602 (2000).

6. Özçelik D, Eralp Y, Öztekin G, Dursun Ş, Uzunismail H, “The impact of penicillamine and zinc inhepatic and brain tissues of copper-overloaded rats,” Trace Elem Elect, 18(1), 34-38 (2001).

7. Eralp Y, Aydıner A, Taş F, Saip P, Topuz E, “Stevens-Johnson Syndrome in a patient receiving anticonvulsant therapy during cranial irradiation,” Am J Clin Oncol, 24(4),347- 50 (2001).

8. Topuz E, Eralp Y, Saip P, Aydıner A, Taş F, Salihoğlu Y, Berkman S, Bengisu E, “The efficacy of a combination chemotherapy including intraperitoneal cisplatinum and mitoxantrone with intravenous ifosfamide in patients with FIGO stage Ic ovarian carcinoma,” Eur J Gynaecol Oncol, 22(1),70-73 (2001).

9. Tas F, Basaran M, Aydiner A, Eralp Y, Topuz E, “5-fluorouracil-induced balanitis in a patient with oesophageal carcinoma,” Clin Oncol (R Coll Radiol),13(3),170-171 (2001).

10. Salihoglu Y, Bilir A, Aydiner A, Erkan M, Tuzlali S, Eralp Y, “Thymidine labeling index in epithelial ovarian cancer,” Int J Gynaecol Obstet,75(2),171-6 (2001).

11. Basaran M, Bavbek ES, Sakar B, Eralp Y, Alici S, Tas F, Yaman F, Dogan O O, Camlica H, Onat H, “Treatment of aggressive non-Hodgkin's lymphoma with doseintensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study,” Am J Clin Oncol,24(6),570-5 (2001).

12. Topuz E, Eralp Y, Aydiner A, Saip P, Tas F, Yavuz E, Salihoglu Y, “The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract,” Eur J Gynaecol Oncol,22(6),469-72 (2001).

13. Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, Bulutlar G, Camlica H, Aydiner A, Topuz E, “Anemia in oncology practice: relation to diseases and their therapies,” Am J Clin Oncol,25(4),371-9 (2002).

14. Eralp Y, Bavbek S, Basaran M, Kaytan E, Yaman F, Bilgic B, Darendeliler E, Onat H, “Prognostic factors and survival in late adolescent and adult patients with small round cell tumors” Am J Clin Oncol,25(4), 418-24 (2002).

15. Alici S, Eralp Y, Saip P, Argon A, Basaran M, Topuz E, Aydiner A, “Clinical characteristics of gestational trophoblastic disease at a single institute,” Tohoku J Exp Med,197(2),95-100 (2002).

16. Alici S, Bavbek SE, Kaytan E, Basaran M, Eralp Y, Onat H, “Aggressive nonHodgkin's lymphoma treated at the Institute of Oncology, Istanbul: treatment, outcome, and prognostic factors,” Am J Clin Oncol, 25(5),502-8 (2002).

17. Alıcı S, Bavbek S, Eralp Y, Argon A, Başaran M, Aydıner A, Tuzlalı S, Topuz E, Onat H, “An atypical presentation of metastatic gestational choriocarcinoma with maxillary sinus and subcutaneous involvement; Report of a case with literature review”, J BUON, 7:373-376 (2002).

18. Alici S, Bavbek SE, Kaytan E, Eralp Y, Onat H, “Prognostic factors in localized aggressive non-Hodgkin's lymphoma,” Am J Clin Oncol, 26(1),1-5 (2003).

19. Eralp Y, Aydıner A,Kizir A,Kaytan E,Oral EN,Topuz E, “Resectable thymoma: treatment outcome and prognostic factors in the late adolescent and adult age group,” Cancer Investigation 21(5),737-43 (2003).

20. Eralp Y, Saip P, Sakar B, Tas F, Aydiner A, Topuz E, “Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix,” Eur J Gynaecol Oncol, 24(3-4):323-6 (2003).

21. Eralp Y, Saip P, Sakar B, Kucucuk S, Aydiner A, Dincer M, Aslay I, Topuz E, “Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix,” Int J Gynecol Cancer, 13(4):497-504 (2003).

22. Bilir A, Ozmen V, Kecer M, Eralp Y, Cabioglu N, Agizhali B, Camlica H, Aydiner A. Thymidine labeling index: prognostic role in breast cancer. Am J Clin Oncol. 2004 Aug;27(4):400-6.

23. Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res. 2004;6(4):R275-83. Epub 2004 Apr 07.

24.Topuz E, Eralp Y, Saglam S, Saip P, Aydiner A, Berkman S, Yavuz E. Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete  remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer. Gynecol Oncol. 2004 Jan;92(1):147-51.

25. Oral EN, Aydiner A, Eralp Y, Topuz E. Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer. Med Oncol. 2005;22(4):367-74.

26.Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault R, Booser D, Buzdar AU, Hortobagyi GN, Arun B. Women age < or = 35 years with primary breast carcinoma: disease features at presentation.Cancer. 2005 Jun 15;103(12):2466-72.

27. Tas F, Ustuner Z, Can G, Eralp Y, Camlica H, Basaran M, Karagol H, Sakar B,Disci R, Topuz E. The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients. Acta Oncol. 2005;44(2):161-7.

28. Karagol H, Saip P, Uygun K, Caloglu M, Eralp Y, Tas F, Aydiner A, Topuz E. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med Oncol. 2007;24(1):39-43.

29. Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, Arun B.Multifocal breast cancer in women < or =35 years old. Cancer. 2007 Oct 1;110(7):1445-50.

30. Pinar Saip; Zeki Aydin; Sinan Berkman; Erkan Topuz. Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol Gynecol Oncol. 2008 Jan;108(1):248-50.

31. Eralp Y, Derin D, Ozluk Y, Yavuz E, Guney N, Saip P, Muslumanoglu M, Igci A, Kucucuk S, Dincer M, Aydiner A, Topuz E. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple negative breast cancer. Ann Oncol 2007 Ann Oncol. 2008 Apr;19(4):669-74.

32. Cicin I, Saip P, Eralp Y, Selam M, Topuz S, Ozluk Y, Aydin Y, Topuz E. Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol. 2008 108 (1):136-40.

33. Eralp Y, Saip P, Aydin Z, Berkman S, Topuz E. Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt. Gynecol Oncol. 2008 Jan;108(1):248-50.

34. Deligezer U, Eralp Y, Akisik EE, Akisik EZ, Saip P, Topuz E, Dalay N. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Lab Med. 2008;46(3):311-7.

35. Derin D, Eralp Y, Guney N, Ozlük Y, Topuz E.Ovarian carcinoma with simultaneous breast and rectum metastases. Onkologie. 2008 Apr;31(4):200-2. 

36. Saip P, Cicin I, Eralp Y, Kucucuk S, Tuzlali S, Karagol H, Aslay I, Topuz E. Factors affecting the prognosis of breast cancer patients with brain metastases. Breast. 2008 Oct;17(5):451-8.

37. Eralp Y, Smith TL, Altundağ K, Kau SW, Litton J, Valero V, Buzdar A,Hortobagyi GN, Arun B.Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol. 2009 Jan;135(1):141-8.

38. Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer. Cancer Invest. 2008 26(7):671-9.

39. Deligezer U, Eralp Y, Akisik EZ, Akisik EE, Saip P, Topuz E, Dalay N. Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer. Ann N Y Acad Sci. 2008 Aug;1137:175-9.

40. Saip P, Cicin I, Eralp Y, Karagol H, Kucucuk S, Cosar Alas R, Yavuz E, Dincer M, Saglam E, Topuz E.Identification of patients who may benefit from the prophylactic ncranial radiotherapy among breast cancer patients with brain metastasis. J Neurooncol. 2008 Dec 20. (e-print).

41. Karagol H, Saip P, Eralp Y, Topuz S, Berkman S, Ilhan R, Topuz E. Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer. Tumori. 2009 Mar-Apr;95(2):207-11.

42. Cicin I, Saip P, Guney N, Eralp Y, Ayan I, Kebudi R, Topuz E. Yolk sac tumours of the ovary: evaluation of clinicopathological features and prognostic factors. Eur J Obstet Gynecol Reprod Biol. 2009 Oct;146(2):210-4. Epub 2009 May 5.

43. Cicin I, Eralp Y, Saip P, Ayan I, Kebudi R, Iyibozkurt C, Tuzlali S, Gorgun O, Topuz E. Malignant ovarian germ cell tumors: a single-institution experience. Am J Clin Oncol. 2009 Apr;32(2):191-6. PubMed PMID: 19307952.

44. Aydiner A, Toker A, Sen F, Bicakci E, Saglam EK, Erus S, Eralp Y, Tas F, Oral EN, Topuz E, Dilege S. Association of clinical and pathological variables with survival in thymoma. Med Oncol. 2011 Nov 6. PubMed PMID: 22057358.

45. Keskin S, Muslumanoglu M, Saip P, Karanlık H, Guveli M, Pehlivan E, Aydoğan F, Eralp Y, Aydıner A, Yavuz E, Ozmen V, Igci A, Topuz E. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracyclinebased neoadjuvant chemotherapy. Oncology. 2011;81(1):30-8. Epub 2011 Sep 9.
PubMed PMID: 21912195.

46. Saip R, Sen F, Vural B, Ugurel E, Demirkan A, Derin D, Eralp Y, Camlica H, Ustuner Z, Ozbek U. Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients. J BUON. 2011 AprJun;16(2):241-6. PubMed PMID: 21766492.

47. Aydiner A, Sen F, Saglam EK, Oral EN, Eralp Y, Tas F, Toker A, Dilege S.Induction with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study. Clin Lung Cancer. 2011 Sep;12(5):286-92. doi: 10.1016/j.cllc.2011.03.030. Epub 2011 May 8. PubMed PMID: 21729649.

48. Keskin S, Muslumanoglu M, Saip P, Karanlık H, Guveli M, Pehlivan E, Aydoğan F, Eralp Y, Aydıner A, Yavuz E, Ozmen V, Igci A, Topuz E. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy. Oncology. 2011;81(1):30-8.

49. Aydiner A, Toker A, Sen F, Bicakci E, Saglam EK, Erus S, Eralp Y, Tas F, Oral EN, Topuz E, Dilege S. Association of clinical and pathological variables with survival in thymoma. Med Oncol. 2012 Sep;29(3):2221-8.

50. Eralp Y, Keskin S, Akışık E, Akışık E, İğci A, Müslümanoğlu M, Yılmaz S, Tunacı M, Çamlıca H, Tuzlalı S, Saip P, Dalay N, Özmen V, Topuz E. Predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2α expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Am J Clin Oncol. 2013 Jun;36(3):215-23.

51. Altundag K, Dizdar O, Ozsaran Z, Ozkok S, Saip P, Eralp Y, Komurcu S, Kuzhan O, Ozguroglu M, Karahoca M. Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain. Onkologie. 2012;35(5):254-8.

52. Ciblak MA; Grip Platformu. Influenza vaccination in Turkey: prevalence of risk groups, current vaccination status, factors influencing vaccine uptake and steps taken to increase vaccination rate. Vaccine. 2013 Jan 7;31(3):518-23.

53. Yildiz I, Tas F, Kilic L, Sen F, Saip P, Eralp Y, Keskin S, Karabulut S,Ciftci R, Serilmez M, Yasasever V, Aydiner A. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer. Cancer Chemother Pharmacol. 2013 Aug;72(2):437-44.

54.Saip P, Eralp Y, Sen F, Karaca H, Ozkan M, Cetin B, Benekli M, Kucukoner M,Isikdogan A, Un O, Basaran G, Onur H. Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial. Breast. 2013 Oct;22(5):628-33.

55.Içli F, Altundağ K, Akbulut H, Paydaş S, Başaran G, Saip P, Doğu GG, Eralp Y, Uslu R, Sevinç A, Onur H, Mandel NM, Sezgin C, Altınbaş M, Güler N, Işıkdoğan A, Gökmen E, Uygun K, Ustüner Z, Yaren A, Demirkan B, Coşkun U, Ata A, Ozkan M, Arican A. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG). Breast Cancer. 2013 Dec 12.

56. Karabulut S, Akşit E, Tas F, Ciftci R, Aydiner A, Yildiz I, Keskin S, Eralp Y,Yasasever CT, Vatansever S, Disci R, Saip P. Is there any diagnostic value of serum  protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma? Tumour Biol. 2014 Jan 5.

57. Gezer U, Keskin S, Iğci A, Tükenmez M, Tiryakioğlu D, Cetinkaya M, Dişci R, Dalay N, Eralp Y. Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy. Oncol Lett. 2014 Aug;8(2):845-848. 

Abstracts and Presentations

1. Ferhanoğlu B, Eralp Y, Arun B, Soysal T, Avanoğlu Y, Ülkü B, Akman N, Başlar Z: Cytokines in multiple myeloma. Proc. 13th Metting of the International Society of
Hematology (European and African Division), 912, İstanbul, Turkey, 1995.

2. Arun B, Eralp Y, Ferhanoğlu B, “Soluble IL-2 receptors in hematologic malignancies,” Proc. 13th Metting of the International Society of Hematology (European and African Division), 619, İstanbul, Turkey, 1995.

3. Eralp Y, Ferhanoğlu B,, Demir M, Hız M, Tüzüner N, Akman N, Türemen E: Primary lymphoma of bone. Proc. 13th Metting of the International Society of Hematology
(European and African Division), 904, İstanbul, Turkey, 1995.

4. Karter Y, Tunçkale A, Köksal S, Eralp Y, Seyahi N, Yaldıran A, Öztürk E, “The antihypertensive effect of doxazocine on the arterial system; Change in resistance and arterial compliance,” Proc. European Federation of Internal Medicine, 1st Congress, Vol 8 (Suppl 1), P 265, Maastricht, Netherlands,1997.

5. Karter Y, Tunçkale A, Eralp Y, Uzun H, Aydın S, Seyahi N, Yaldıran A, Öztürk E, “Cytokines interrelationships and their association with acute phase proteins in Hodgkin's Disease,” Proc. European Federation of Internal Medicine, 1st Congress, Vol 8 (Suppl 1), P 376, Maastricht, Netherlands,1997.

6. Karter Y, Uzun H, Aydın S, Tunçkale A, Eralp Y, Seyahi N, Yaldıran A, Öztürk E, “Cytokines interrelationships and their association with acute phase proteins in
Rheumatoid Arthritis,” Proc. European Federation of Internal Medicine, 1st Congress, Vol 8 (Suppl 1), P 372, Maastricht, Netherlands,1997.

7. Topuz E, Alıcı S, Taş F, Eralp Y, Bulutlar G, Saip P, Aydıner A, “Clinical characteristics of gestational trophoblastic disease (GTD) at a single institute”, 9
th International Congress on Anti-cancer Treatment, PP15 ,Paris, France, 1999.

8.Alıcı S, Aydiner A, Eralp Y, Bulutlar G, Topuz E, “An atypical presentation of a case with metastatic choriocarcinoma with maxillary sinus and subcutaneous tissue
involvement”, Proc. 9th International Congress on Anti-cancer Treatment, PP16, Paris, France, 1999.

9. Aydıner A, Topuz E, Eralp Y, Taş F, Saip P, “A case with multiple pulmonary nodules and renal vasculitis,” 10th International Congress on Anti-cancer Treatment, P242 ,Paris, France, 2000.


10. Eralp Y, Bavbek S, Başaran M, Kaytan E, Yaman F, Bilgiç B, Darendeliler E, Onat H, “Prognostic factors and survival in adult patients with small round cell tumors,” Proc. 25th Meeting of the European Society of Medical Oncology, Vol 11(Suppl 4), P 576, Hamburg,
Germany, 2000.

11. Topuz E, Eralp Y, Aydıner A, Saip P, Taş F, Salihoğlu Y, “The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract,” Proc. 25th
 Meeting of the European Society of Medical Oncology, P 354, Hamburg, Germany, 2000.

12. Bavbek S, Başaran M, Saip S, Eralp Y, Sakar B, Onat H, “Neurologic late toxicity in testicular cancer patients treated with bleomycin, etoposide and cisplatin (bep) combination chemotherapy”, Proc. 25th Meeting of the European Society of Medical Oncology, P 345, Hamburg, Germany, 2000.

13. Özger H, Eralp Y, Kaytan E, Eralp L, Yaman F, Bavbek S, Başaran M, Bilgiç B, Darendeliler E, Onat H, “Prognostic factors and survival in patients with non-metastatic soft tissue sarcoma of the extremities,” Proc. Asia-Pacific Musculosceletal Tumor Association 3rd  Meeting, P33, Hong Kong, 2000.

14. Eralp Y, Toptani S, Tas F, Camlica H, Topuz E, “Circulating Her-2/neu levels in patients with melanoma”, Proc. AACR-NCI-EORTC International Conference, 151-152,
P746, Miami, USA, 2001.

15. Topuz E, Aydıner A, Eralp Y, Saip P, Taş F, Salihoğlu Y, “Efficacy of paclitaxel in combination with intraperitoneal cisplatinum in patients with advanced ovarian cancer”, Proc. 11th the European Cancer Conference, Vol 37(Suppl 6), P 1196, Lisbon, Portugal, 2001.

16. Eralp Y, Aydıner A,Kizir A,Kaytan E,Oral EN,Topuz E, “Resectable thymoma: treatment outcome and prognostic factors in the late adolescent and adult age group,”
Proc. 12th the European Cancer Conference, Eur J Cancer, Vol 1(No 5), P130, Copenhagen, Denmark, 2003.

17. Eralp Y, Smith TL, Kau SW, Valero V, Buzdar A, Hortobagyi GN, Arun B. Body mas index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with
localized breast cancer aged 35 years or younger. JOURNAL OF CLINICAL ONCOLOGY 22 (14): 27S-27S 600 Suppl. S, JUL 15 2004, Abs 600, Annual ASCO Meeting 2004, June 5 8, 2004, New Orleans, Lousiana, USA.

18. Aydiner A, Topuz E, Eralp Y, Kaytan E, Oral EN, Kizir A . Induction chemotherapy with carboplatin and weekly paclitaxel followed by concomitant chemoradiation in locally advanced non-small cell lung cancer. JOURNAL OF CLINICAL ONCOLOGY 22 (14): 683S-683S 7270 Suppl. S, JUL 15 2004, Abs. 7270, Annual ASCO Meeting 2004, June 5-8, 2004, New Orleans, Lousiana, USA.

19. Topuz E, Tas F, Argon A, Yildiz DD, Oguz H, Yasasever V, Eralp Y, Aydiner A . Serum levels of leptin and proinflammatory cytokinesin advanced stage non-small cell 
lung cancer. JOURNAL OF CLINICAL ONCOLOGY 23 (16): 189S-189S Part 1 Suppl. S, JUN 1 2005, Abst 2594, Annual ASCO Meeting 2005, May 14-17, 2005, Orlando, Fl, USA.

20. Karagol H, Saip P, Uygun K, Caloglu M. , Eralp Y, Tas F, Aydiner A , Topuz E. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. ANNALS OF ONCOLOGY 17: 174-174 Suppl. 9, 2006; P551, 31th ESMO Congress, 29 Sept-3 Oct 2006, Istanbul, TURKEY.

21. Karagol H, Saip P, Uygun K, , Eralp Y, Topuz S, Berkman S, Ilhan R, Topuz E. Factors related with recurrence after complete pathologic response to post- operative chemotherapy in patients with epithelial ovarian cancer. P553, ANNALS OF ONCOLOGY 17: 174-174 Suppl. 9, 2006. 31th ESMO Congress, 29 Sept-3 Oct 2006, Istanbul, TURKEY.

22. Saglam EK, Aydiner A, Sakallioglu B, Ozturk B, Eralp Y, Saip P, Oral EN, Kizir A, Topuz E. Induction chemotherapy followed by chemoradiotherapy in patients with stage IIIA-B non-small cell lung cancer (NSCLC). P771, ANNALS OF ONCOLOGY 17: 229-229 Suppl. 9, 2006, 31th ESMO Congress, 29 Sept-3 Oct 2006, Istanbul, TURKEY.

23. Eralp Y, Duygu Derin, Yasemin Ozluk, Ekrem Yavuz, Nese Guney, Pinar Saip, Mahmut Muslumanoğlu, Abdullah İgci, Seden Kucucuk, Maktav Dincer, Adnan Aydiner
and Erkan Topuz. “MAPK expression is associated with poor outcome in patients with hormone receptor negative breast cancer.” Proc 30th Annual San Antonio Breast Cancer Symposium. P 6025, Dec 13-16, 2007, San Antonio, TX, USA.

24. Özmen V, Müslümanoğlu M, İğci A, Canbay E, Özçınar B, Mudun A, Eralp Y, Saip P, Tuzlali S, Dinçer M, Dağoğlu T, Keçer M, Parlak M. Is the sentinel lymph node biopsy accurate for patients with initially clinically axilla-positive locally advanced breast cancer after neoadjuvant chemotherapy? Cancer Research 69 (2):337 S-338S, 2009; 31th Annual San Antonio Breast Cancer Symposium, Dec 10-14, 2008, San Antonio, TX, USA.

25. Deligezer U, Eralp Y, Akisik EZ, et al.Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer . 5th International Conference on Circulating Nucleic Acids in Plasma and Serum, AUG 23-27, 2007 Moscow, RUSSIA;CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM; ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Volume: 1137 Pages: 175-179 Published: 2008

26. Basaran G, Okkan S, Caglar H, et al.Immunohistochemically Defined T1N0 Breast Cancer Subgroups Have Different Clinical Outcomes. A Retrospective Turkish Oncology
Group Study. 32nd Annual San Antonio Breast Cancer Symposium, DEC 09-13, 2009 San Antonio, TX. CANCER RESEARCH Volume: 69 Issue: 24 Pages: 701S-701S  Supplement: Suppl. 3 Published: DEC 15 2009

Publications

The Declarations Summary That are Pressed in Scientific Meetings

1. Topuz E, Aydıner A, Eralp Y, Uygun K, Saip P, Taş F, “Preliminary results of a phase II study with mitomycin-C and vinorelbine for the treatment of metastatic breast cancer”, Proc. ASCO 35th Annual Meeting of the American Society of Clinical Oncology, Vol 18, 138a, Atlanta, USA, 1999.

2. Alıcı S, Kaytan E, Şakar B,Bulutlar G, Eralp Y, Argon A, Aykan F, “Rectal cancer in young patients: Characteristics and outcome”, 25th ESMO Congress,
a245,Hamburg,Germany, 2000. 

3. Alıcı S, Bulutlar G, Saip P, Eralp Y, Aydıner A, Topuz A, “Oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease”, 10th International Congress on Anti-cancer Treatment, ab013 ,Paris, France, 2000. 

4. Topuz E, Aydıner A, Saip P, Eralp Y, Taş F, Salihoğlu Y, Tenekeci N, “Correlation of
CA 125 levels and computerized tomography imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer”, Proc. 36th ASCO Annual Meeting of the American Society of Clinical Oncology, Vol 19, 400a, New Orleans,USA, 2000.

5. Basaran M, Hafiz G, Sakar B, Eralp Y, Bavbek S, Darendeliler E, Onat H: Hearing loss in testicular cancer patients treated with bleomycin, etoposide and cisplatinum (BEP) combination chemotherapy Proc. 36th ASCO Annual Meeting of the American Society of Clinical Oncology, Vol 19, 346a, New Orleans,USA, 2000.

6. Topuz E, Eralp Y, Aydiner A, Saip P, Taş F, “Intraperitoneal Chemotherapy in Patients with Peritoneal Malignant Mesothelioma”, Proc. 37 th ASCO Annual Meeting of the American Society of Clinical Oncology, Vol 20, 2286a, San Francisco,USA, 2001.

7. Şakar B, Başaran M, Argon A, Alıcı A, Eralp Y, Kaytan E, Buğra D, Aykan F, Topuz E, “The link between local recurrence and survival in patients with primary rectal cancer”, Proc. 38th ASCO Annual Meeting of the American Society of Clinical Oncology, Vol 21, 2372a, Orlando,USA, 2002.

8. Alıcı S, Bavbek S, Kaytan E, Eralp Y, Onat H, “Prognostic factors in localized aggressive non-Hodgkin lymphoma”, Proc. 38th ASCO Annual Meeting of the American
Society of Clinical Oncology, Vol 21, 2641a, Orlando,USA, 2002.

9. Y. Eralp, B. Sakallioglu, S. Kucucuk, S. Tuzlali, P. Saip, A. Igci, M. Muslumanoglu, A. Aydiner, E. Topuz. Impact of adjuvant chemotherapy with respect to level of hormone receptor expression in patients with hormone responsive breast cancer: Implications for endocrine resistance. J Clin Oncol 26: 2008 (suppl; abstr 11563); . 44th ASCO Annual Meeting of the American Society of Clinical Oncology, Vol 21, 2372a, Chicago,USA, 2008.

Books and Section Authorships

1. Eralp Y, Aydıner A, “Yaygın küçük hücreli akciğer kanserlerinde kemoterapi”, Akciğer kanserleri: Tanı ve tedavide temel ilkeler ve uygulamalar. Ed. K. Engin, N.
Özyardımcı, 183-188, Avrupa Tıp Kitapçılık, Istanbul 2001.

2. Aydıner A, Eralp Y, “Kanser tanısında fizik muayene”, Kanser hastasına yaklaşım: Tanı tedavi ve takipte sorunlar. Ed. H. Onat, N. Molinas Mandel, 5-10, Nobel Tıp
Kitabevleri, İstanbul 2002.

3. Eralp Y, “Kanser hastasında kardiyolojik sorunlar”, Kanser hastasına yaklaşım: Tanı tedavi ve takipte sorunlar. Ed. H. Onat, N. Molinas Mandel, 165-170, Nobel Tıp
Kitabevleri, İstanbul 2002.

4. Eralp Y, Aydıner A, “Meme kanserinde yeni evreleme sistemi”, Meme Kanseri. Ed. E. Topuz, A. Aydıner, M. Dinçer, 132-135, Nobel Tıp Kitabevleri, İstanbul 2003.

5. Aydıner A, Eralp Y, “Gebelik ve meme kanseri”, Meme Kanseri. Ed. E. Topuz, A. Aydıner, M. Dinçer, 563-570, Nobel Tıp Kitabevleri, İstanbul 2003.

6. Aydıner A, Eralp Y, “Kemik metastazlarında ilaç tedavisi”, Meme Kanseri. Ed. E. Topuz, A. Aydıner, M. Dinçer, 631-641, Nobel Tıp Kitabevleri, İstanbul 2003.

7. Eralp Y, Saip P. “Rare neuroendocrine tumors”, Neuroendocrine tumors of the gastroenteropancreatic system. Ed. Yalcın S. 205-14. Ankara, 2006.

Attribution

1. Dobrucalı A, Tuncer M, Eralp Y, Göksel S, Altın M, Dinç İ, “One-day high dose combined therapy of H. Pylori infection,” Dig Dis Sci, 42(10), 2169-70 (mektup) (1997). (X1)

2. Taş F, Aydıner A, Topuz E, Çamlıca H, Saip P, Eralp Y, “Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer,” Acta Oncol, 38(8),1011-5 (1999). (X8)

3. Eralp Y, Bavbek S, Başaran M, Kaytan E, Yaman F, Eralp L, Özger H, Bilgiç B, Kalaycı G, Onat H, “Prognostic factors and survival in patients with metastatic soft tissue sarcoma,” J Balkan Union Oncol, 5,281-6 (2000). (X1)

4. Topuz E, Aydıner A, Saip P, Eralp Y, Taş F, Salihoğlu Y, Berkman S, Bengisu E, “Correlations of serum CA-125 levels and computerized CT imaging with laparotomic
findings following intraperitoneal chemotherapy in patients with ovarian cancer,” Eur J Gyn Oncol, 2(6),599-602 (2000). (X6)

5. Özçelik D, Eralp Y, Öztekin G, Dursun Ş, Uzunismail H, “The impact of penicillamine and zinc inhepatic and brain tissues of copper-overloaded rats,” Trace Elem Elect, 18(1), 34-38 (2001). (X1)

Rewards and Certificates

  • 1991 Diplomate; Board of Medicine
  • 1997 Diplomate; Board of Internal Medicine
  • 2001 Diplomate; Board of Medical Oncology

Publications

Editorship and Scientific Arbitrage

  • Reviewer: BioMed Central; 2007
  • Reviewer: Journal Of Internal Medical Sciences; 2006-present
  • Editorial Board and Reviewer: Journal of Breast Health; 2006-present

Studies

  • 1st Place in basic research: 17th National Cancer Conference; 19-23 April 2007 

Research Projects

  • Mechanisms of drug resistance and predictive factors
  • Identification of genetic markers that have prognostic and predictive roles in cancer therapy
  • Integrating immunotherapy and chemotherapy for cancer treatment

Do you want to keep informed about us?
florence nightingale hastanesi

Copyright 2016 Group Florence Nightingale Hospitals. All rights reserved.

The information on this website is not intended to replace any medical advice given by physicians with access to your detailed medical history.